Serum β2-MG, sCHE, and PSGL-1 Expression in Patients with Esophageal Cancer and Their Association with Postoperative Lung Infection After Mediastinoscopy
-
摘要:目的
探究食管癌患者血清β2-MG、sCHE、PSGL-1表达及其与纵隔镜术后肺部感染的关系。
方法选取118例食管癌患者。根据患者术后是否发生肺部感染分为感染组和非感染组。全自动微生物鉴定系统检测肺部感染病原菌。ELISA检测β2-MG、sCHE、PSGL-1水平。多因素Logistic回归分析食管癌患者术后肺部感染的影响因素。绘制ROC曲线分析血清β2-MG、sCHE、PSGL-1对食管癌患者术后肺部感染的评估价值。
结果38例术后肺部感染患者痰液中分离出52株菌株,其中革兰氏阴性菌35株(67.31%),革兰氏阳性菌14株(26.92%)以及真菌3株(5.77%)。感染组和未感染组长期吸烟史比较差异具有统计学意义(P<0.05)。感染组血清β2-MG、PSGL-1水平显著高于未感染组(P<0.05),sCHE水平显著低于未感染组(P<0.05)。肺部感染轻度、中度和重度组血清β2-MG、PSGL-1水平依次升高(P<0.05),sCHE水平依次降低(P<0.05)。长期吸烟史、β2-MG和PSGL-1为影响食管癌患者术后肺部感染的危险因素(P<0.05),sCHE为保护因素(P<0.05)。血清β2-MG、sCHE、PSGL-1评估食管癌患者术后肺部感染的AUC为0.807、0.845、0.800,三者联合评估食管癌患者术后肺部感染的AUC为0.954,三者联合优于单独评估(Z联合vs. β2-MG=2.576、Z联合vs. sCHE=2.623、Z联合vs. PSGL-1=2.574,均P<0.05)。
结论食管癌术后肺部感染患者血清β2-MG和PSGL-1水平显著升高,sCHE水平显著降低,还与肺部感染程度有关,联合检测可提高对患者术后肺部感染的评估价值。
Abstract:ObjectiveTo investigate serum β2-MG, sCHE, and PSGL-1 expression in patients with esophageal cancer and their relationship to lung infection after mediastinoscopy.
MethodsA total of 118 patients with esophageal cancer were selected and divided into infected and uninfected groups according to whether they developed lung infection after surgery. An automatic microbiological identification system was used to detect the pathogenic bacteria of lung infection. ELISA was used to detect the levels of β2-MG, sCHE, and PSGL-1. Multivariate logistic regression was used to analyze the influencing factors of postoperative lung infection in patients with esophageal cancer. ROC curves were plotted to analyze the assessment value of serum β2-MG, sCHE, and PSGL-1 on postoperative lung infection.
ResultsFifty-two strains of bacteria were isolated from the sputum of 38 patients with postoperative lung infections, and these included 35 (67.31%) Gram-negative, 14 (26.92%) Gram-positive, and 3 (5.77%) fungal strains. The difference in long-term smoking history between the infected and uninfected groups was statistically significant (P<0.05). Serum β2-MG and PSGL-1 levels were significantly higher and sCHE levels were significantly lower in the infected group than in the uninfected group (P<0.05). Serum β2-MG and PSGL-1 levels were sequentially higher (P<0.05) and sCHE levels were sequentially lower (P<0.05) in the mild, moderate, and severe lung infection groups. Long-term smoking history, β2-MG, and PSGL-1 were risk factors affecting postoperative lung infection in patients with esophageal cancer (P<0.05), and sCHE was a protective factor (P<0.05). The AUCs of serum β2-MG, sCHE, and PSGL-1 for assessing postoperative lung infections were 0.807, 0.845, and 0.800, respectively, and the AUC of the three combined factors for assessing postoperative lung infections was 0.954, which was superior to that assessed individually (Zcombination vs. β2-MG=2.576, Zcombination vs. sCHE=2.623, Zcombination vs. PSGL-1=2.574, all P<0.05).
ConclusionThe serum levels of β2-MG and PSGL-1 increase and the sCHE level decreases in patients with esophageal cancer and postoperative pulmonary infection, which are also related with lung infection. Combined testing can improve the evaluation value of postoperative pulmonary infection in patients.
-
0 引言
随着中医药治疗恶性肿瘤标准化、规范化研究的日益深入,中医药对恶性肿瘤的疗效得到越来越多的肯定[1-2]。为使中医药在恶性肿瘤治疗的各阶段均发挥特色优势,对恶性肿瘤患者进行全生命周期管理。在“固本清源”理论体系的基础上[3],林洪生教授根据现代医学的临床路径,提出“五治”的肿瘤治疗理念,旨在对患者进行分阶段、规范化、辨证与辨病相结合施治。同时,为满足肿瘤患者康复需求,提高患者获益度,林教授将中医特色的康养疗法加入到现代肿瘤康复工作中,提出“五养”的肿瘤康复理念。现将“五治五养”在中医药防治恶性肿瘤全程管理中的应用总结如下。
1 “五治”的概念
2014年,由林教授主编的《恶性肿瘤中医诊疗指南》首次提出中医药分阶段、规范化贯穿现代医学治疗始终的恶性肿瘤治疗理念,创新性地提出了“五治”的概念,即:防护治疗、巩固治疗、维持治疗、加载治疗和单纯中医药治疗。“五治”是“固本清源”理论体系的实践精髓,是中西医结合防治恶性肿瘤的纲领。
1.1 防护治疗
中医防护治疗以减轻手术、放化疗、靶向治疗、内分泌治疗等治疗手段引起的不良反应,促进机体功能恢复,改善症状,提高生存质量为目的,遣方用药当以扶正固本为主,慎用或禁用祛邪清源药,以防进一步损伤人体正气。根据抗肿瘤治疗的类型与患者气血阴阳、脏腑经络的功能,合理运用“补” “调” “和” “益”等方法进行防护。
化疗药物为毒邪,易伤及气血、损伤脾胃,日久造成肝肾亏虚。针对化疗期间常见的消化道毒性和骨髓抑制,林教授常用法半夏-淡竹茹,生黄芪-焦白术-鸡血藤-白芍,怀牛膝-川续断等作为化疗期间的基础防护治疗,以健脾和胃,益气养血,滋补肝肾。若血红蛋白或白细胞低下,加阿胶珠、菟丝子、补骨脂补血生髓;伴大便秘结,加肉苁蓉、玄参温润通便;伴腹泻便溏,加诃子、芡实、豆蔻化湿止泻。放射线属热毒邪,易耗气伤阴。林教授针对放疗证属阴亏津少、血热毒结者,常用天冬-麦冬,沙参-石斛,太子参-焦白术-鸡血藤-白芍,赤芍-蒲公英等药物组合,以养阴生津,活血解毒,凉补气血;并予二黄煎(黄连30 g、黄柏30 g、虎杖30 g)外用预防放射性皮炎[4]。对于乳腺癌内分泌治疗的患者,林教授谨守“肝郁”病机,结合肝的生理特性遣方用药,常用醋柴胡-炒栀子以清肝热,解肝郁,白芍-鸡血藤养血柔肝,配合天冬-麦冬滋阴降火,香附-佛手-枳壳等理气和中,随证加减以缓解内分泌治疗导致的围绝经期综合征。
现代医学各类新药、新疗法层出不穷,中医防护治疗亦需自我迭代以适配繁多的抗肿瘤治疗方案。谨守病机,根据不同抗肿瘤治疗可能出现的不良反应,将中医外治法、非药物疗法等进行组合,发挥中医综合防护功效,使患者耐受全疗程抗肿瘤治疗。
1.2 巩固治疗
中医巩固治疗以防止复发转移,改善症状,提高生存质量为目的,适用于手术后无需辅助治疗或已完成辅助治疗的患者,遣方用药以扶正固本为主,兼以祛邪清源。
以早期肺癌术后患者为例,巩固治疗的目的为防止恶性肿瘤复发和改善症状。“肺主气司呼吸”“肺为娇脏,喜润恶燥”,根据肺的生理功能和生理特性,林教授临证常用黄芪-白术-防风,天冬-麦冬-北沙参等益气养阴药恢复肺的生理功能[5]。所谓“血不独生,赖气以生之,气无所附,赖血以附之”,佐以养血、活血之品,常用白芍-鸡血藤祛瘀生新;配合培土生金法、金水相生法补益肺脏。在扶正固本的基础上,林教授会结合患者的理化检查、肿瘤病理类型,正邪盛衰等情况,配合使用3~4味祛邪清源的中药,常用金荞麦-白英-土茯苓。为避免祛邪清源中药耐药,需定期更换清热解毒、活血祛瘀、化痰散结等祛邪药物,时间以2~3个月为1个周期,每个治疗周期内可用白花蛇舌草、预知子、半边莲、山慈菇、龙葵、蛇莓、凌霄花、梅花中的2~3味药替换上述金荞麦、白英、土茯苓中的2~3味药。早期肺癌术后的患者,一般建议行2~3年的中医药治疗,待患者度过复发危险期,方可停药。
针对不同类型、不同危险程度的患者,巩固治疗的疗程与周期不尽相同,临证中应灵活调整扶正与祛邪的药物比例,以祛邪不伤正,扶正不留邪。
1.3 维持治疗
中医维持治疗以控制肿瘤生长,延缓疾病进展或下一阶段放化疗时间,提高生存质量,延长生存时间为目的,适用于无法手术切除,经放化疗后疾病稳定的带瘤患者,遣方用药以祛邪清源为主,兼顾扶正固本。
与中医巩固治疗期间的患者相比,维持治疗期间的患者仍存在肿瘤负荷,肿瘤进展或者转移风险较高,林教授临证视患者的肿瘤病位、病性、病势,在固本的基础上,选用活血化瘀法、理气化痰法、清热解毒法、软坚散结法以减缓肿瘤进展的病程。血瘀者选用莪术、鸡血藤、赤芍、丹参等;气滞者选用柴胡、佛手柑、香附、枳壳;痰凝者选用茯苓、猪苓、法半夏、瓜蒌等;热毒者选用金银花、连翘、蒲公英、白英、金荞麦等;癥瘕积聚者选用山慈菇、夏枯草、浙贝母等[6]。在祛邪清源的同时,兼顾扶正固本。根据患者先前接受的抗肿瘤治疗,气血五脏虚损情况,使用培补脾肾、益气养阴、健脾和胃等治法。
针对肿瘤转移高风险的患者,林教授主张“先安未受邪之处”。如激素受体阳性型乳腺癌易发生骨转移,林教授临证时选用补骨脂、续断、杜仲、牛膝等补肾壮骨之品预防骨转移;小细胞肺癌患者易发生脑转移,林教授常用益智仁、覆盆子等中药补肾益髓,在应用祛邪清源药物的基础上,选择天麻、钩藤等药物载药上行,直达病灶,预防脑转移。
中医维持治疗在祛邪清源与扶正固本之间寻求平衡,既发挥调节机体内环境以遏制肿瘤生长的作用,又杀灭肿瘤细胞。在维持治疗期间,应该密切关注患者的理化检测,若肿瘤进展,应尽快选择相应的现代医学抗肿瘤治疗,维持治疗也相应转化为防护治疗或加载治疗。
1.4 加载治疗
中医加载治疗适用于有并发症、不能耐受多药化疗而选择单药化疗的患者(老年患者PS评分为2分)。为弥补化疗剂量不足的遗憾,加载治疗期间的遣方用药以祛邪清源为主,配合单药化疗杀灭癌细胞;兼以扶正固本,减少化疗不良反应,确保患者完成规定周期的化疗。为配合化疗杀伤癌细胞,加载治疗可根据肿瘤所在部位,患者气血阴阳状况,并结合中药的性味归经及现代药理研究的结果,选用相应的抗肿瘤中药。如肺癌常用金荞麦、白英、白花蛇舌草、预知子等清热解毒,归肺经的中药;乳腺癌常用夏枯草、蒲公英、蛇莓、凌霄花等消肿散结,归肝经的药物。对于肿瘤负荷大,癥瘕结聚较甚的,选用山慈菇、莪术、昆布等软坚散结、消积除癥之品[7]。
加载治疗和防护治疗在化疗期间各有侧重。联合化疗对癌细胞杀伤力强但正气损伤大,故配合防护治疗,重在扶正固本,禁用或慎用祛邪清源中药。单药化疗正气损伤小但抗癌效果弱,故配合加载治疗,重在祛邪清源,兼以扶正固本。加载治疗期间应避免“杀伐过度”,一般使用3~4味具有抗肿瘤作用的中药,剂量一般不超过15 g,且每隔2~3个月换用药物,防止耐药及毒性蓄积。并严密关注患者的化疗反应,若出现严重的不良反应,加载治疗亦调整为防护治疗。随着靶向治疗[8]和免疫治疗[9]的普及,加载治疗也可运用于不能耐受标准剂量靶向治疗、免疫治疗的患者,以增效减毒,达到控制肿瘤、延长生存、提高生活质量的目的。
1.5 单纯中医药治疗
单纯中医药治疗以控制肿瘤、稳定病情、提高生存质量、延长生存期为目的,尤其适用于老年晚期、体力状态差,不适合或不接受手术、放疗、化疗、分子靶向治疗的患者。在四诊合参、辨证论治的基础上,结合现代医学对肿瘤病理特性、病程转归的研究,辨病辨证相结合施治。
晚期肿瘤患者常因肿瘤侵犯而出现各种兼症,林教授认为对兼症的管理是改善患者不适症状,提升生活质量的关键。如脑转移导致的脑水肿,症见头晕头疼,林教授常用茯苓、猪苓、泽泻,利湿行水,钩藤、牛膝息风止痉;若见颅内压升高导致恶心呕吐,则用法半夏、淡竹茹,温阳化气、利湿行水[10]。若出现胸水,症见喘闷,则用浙贝母、桑白皮、茯苓、猪苓、泽泻等泻肺利水;若见黄疸,则用茵陈、虎杖等利湿退黄,柴胡、香附、栀子、枳壳疏肝理气,白芍、鸡血藤养血柔肝;若出现癌性疼痛,则用延胡索活血行气止痛,并根据疼痛的性质和部位,配合具有活血化瘀、化痰散结功效的中药,及相应的引经药。
针对单纯中医药治疗患者,应谨守病机,结合现代医学对疾病转归的认识,在控制肿瘤的同时,重视对不适症状的管理,以延长生存,提高生活质量。
2 “五养”的概念
“五养”康复即饮食调养、运动调养、心理调养、功能调养、膏方调养,是在中医理论指导下,结合中医传统康复技术和现代康复手段,对肿瘤患者进行全生命周期健康管理的中医肿瘤综合康复模式。经循证医学验证,中医肿瘤综合康复方案具有降低术后复发转移率、改善患者不适症状、调整患者不良情绪、提高患者生存质量等优势[11]。
2.1 饮食调养
饮食调养是在中医基础理论指导下,融合现代营养学理论,遵循“三因制宜”的原则,根据食物的性味、归经、功能作用合理调配膳食的调养模式。应教育患者避免过度进补或担心“发物”过度忌口,不宜食用腌、熏、烧烤类食物,不吃发霉变质的食品及含有防腐剂的罐头食品和香肠,戒除烟酒嗜好,避免暴饮暴食。并根据肿瘤特性进行相应饮食指导,如肺癌患者慎食羊肉、狗肉、辛辣刺激等食物,激素受体阳性的乳腺癌患者忌蜂王浆等富含雌激素的食品[12]。在制定个体化饮食调养方案时,还需考虑患者的营养状况、消化能力、饮食习惯、体质偏颇、肿瘤病程及治疗阶段。如术后患者建议进食高血红蛋白、高维生素C、高铁元素的食物,早期先进食易消化食物,待能正常饮食后可制定个性化菜谱,补气可选小米、山药、鸡肉等,血虚可用红豆、紫米、红枣、菠菜、鳝鱼等[13-14]。
2.2 运动调养
运动调养是中医传统功法与运动康复学的有机结合,通过科学适度的运动,改善患者因肿瘤本身或抗肿瘤治疗导致的不适和虚弱,提高机体代谢水平,增强体质,提高免疫力。《吕氏春秋》曰:“流水不腐,户枢不蠹,动也”。林教授主张运动调养应该视患者体质情况而定,运动量以微微出汗而不喘、疲劳休息后能缓解为度,做到动静结合、张弛有度、持之以恒,提倡轻松愉快的运动方式,调身、调息、调心三者兼顾,切忌“暴力运动”,过劳或过逸。中医传统功法如五禽戏、太极拳、太极剑、八段锦、易筋经等可适用于肿瘤患者日常运动调养,在呼吸之中感受肢体的收缩与舒展、心神的安宁祥和,以达到五脏六腑皆安定的目的。循证医学研究亦证实,中医传统功法可改善肿瘤患者的不适症状,促进术后康复[15-16]。因此,中医理论指导下的运动调养是中医肿瘤康复不可缺少的一部分。
2.3 心理调养
《黄帝内经》言:“悲哀愁忧则心动,心动则五脏六腑皆摇。”不良的心理状况会对全身产生负面影响,不利于肿瘤患者康复。肿瘤作为心身疾病,医生应时刻关注患者心理动态,必要时由心理医生和临床医生通力配合进行诊治。五音疗法作为中医特色心理疗法,是根据五脏生克制化关系选择相应乐曲来治疗疾病的干预手段。研究表明,五音疗法可改善患者的焦虑、抑郁等不良情绪[17]。此外,劝说开导法、移情易性法、暗示解惑法、顺情从欲法、个体咨询、团体心理干预、正念疗法、冥想等中、西医特色心理疗法可组合使用,共同调理患者的心理状态。同时,联合患者家属/家庭、社会的力量,打造肿瘤患者康复友好型环境,帮助其快速回归家庭与社会。
2.4 功能调养
功能调养以恢复患者生理功能为目的,应视患者功能障碍特点,制定相应的功能调养方案。如肺癌围手术期的患者,可采用中医呼吸吐纳训练来恢复肺功能;化疗相关恶心呕吐可采用耳穴压豆缓解;化疗药物毒性导致手足麻木者,可采用益气活血通络的中药泡洗方泡手泡脚,恢复神经敏感度;肿瘤术后胃肠功能障碍或术后肢体不利者,可采用针刺治疗等。功能调养手段众多,根据患者个体情况选择适宜的调养方法,发挥中医肿瘤综合康复优势,以促进快速康复。
2.5 膏方调养
膏方是在中医理论指导下,精制加工的大型复方成药,其具有用量少、有效成分含量高、味道较好且便携的特点。临床研究证实了膏方调节免疫功能、缓解症状、提升生活质量的疗效,且未见不良反应[18-19]。肿瘤患者常呈现“虚实夹杂,以虚为主”的病机特点,膏方组方应有侧重。如术后防护治疗期间的膏方调养以补气养血,健脾益胃为主,但不可一味进补,应考虑患者痰湿、血瘀等病理因素,加入行气、活血类药物;在维持治疗和加载治疗期间,膏方组方中适当增加具有抗肿瘤成分中药的比例,灵活调整膏方中扶正固本与祛邪清源的中药比例,对患者大有裨益[20]。
3 总结
“固本清源”理论指导下的“五治五养”在肿瘤防治与康复中具有独特的理论和方法优势。“固本清源”理论通过整体观念、辨证论治,辨识正邪盛衰,辨明用药时机,以求“祛邪不伤正,扶正不留邪”,既固护机体正气,又祛除肿瘤致病因素,从源头控制肿瘤形成。“五治五养”是在“固本清源”理论指导下,针对不同人群、治疗阶段、疾病进程,将辨病与辨证相结合,中医药与现代医学抗肿瘤策略相融合,对肿瘤患者实施全程管理的实践精髓。“五治”侧重于与现代医学治疗手段协同,旨在减毒增效、延长患者生存期,在恶性肿瘤全程管理中,“五治”之间既相互独立,又相互转换,形成中医防治恶性肿瘤的全程管理的核心。“五养”则强调配合“五治”,对抗肿瘤治疗之外的不适进行干预,以促进康复、提高生活质量。在临床实践中,“五治五养”的使用需根据患者的具体肿瘤病程、体质偏颇、治疗阶段和功能障碍进行个性化、动态调整。
“五治五养”为恶性肿瘤患者提供了全生命周期的防治与康复管理,既关注“治病”,又重视心身康复,助力患者以更健康积极的状态重返社会。推广“五治五养”有助于减轻社会疾病负担,优化卫生资源分配,提升公众对肿瘤及健康的认识,构建肿瘤患者康复友好型社会,提升整体社会健康水平。后续,“五治五养”将不断更新完善,适配精准医疗、大数据医疗模式,融合基因检测、人工智能等现代科技,为患者提供个性化治疗方案;并利用互联网技术,将中医药治疗与康复服务扩展至偏远地区,为肿瘤患者带来更全面的获益,为医药卫生事业的发展做出更大贡献。
Competing interests: The authors declare that they have no competing interests.利益冲突声明:所有作者均声明不存在利益冲突。作者贡献:冯 雨:构思与设计及实施研究、统计学处理、数据收集与整理、撰写论文钱如林:文章质量控制与审查崔东、常超颖:数据收集与整理陈茂林:统计学处理、图表绘制 -
表 1 术后肺部感染病原菌分布情况
Table 1 Distribution of pathogenic bacteria in postoperative lung infections
Bacteria Quantity (plants) Proportions (%) Gram-negative bacteria 35 67.31 Klebsiella pneumoniae 15 28.85 Pseudomonas aeruginosa 10 19.23 Acinetobacter baumannii 5 9.62 Escherichia coli 3 5.77 Other 2 3.85 Gram-positive bacteria 14 26.92 Staphylococcus aureus 6 11.54 Hemolytic Staphylococcus 4 7.69 Enterococcus faecalis 3 5.77 Other 1 1.92 Fungi 3 5.77 Pseudomonas albicans 3 5.77 Total 52 100.00 表 2 感染组和未感染组患者一般资料的比较
Table 2 Comparison of general information of patients between infected and uninfected groups
General
informationInfected group
(n=38)Uninfected
group(n=80)t/χ2 P Age(years) 63.12±5.38 64.16±5.37 0.982 0.328 Gender 0.038 0.845 Male 24(63.16) 52(65.00) Female 14(36.84) 28(35.00) BMI(kg/m2) 22.89±1.67 22.91±1.68 0.0681 0.952 Duration of
disease(years)7.81±2.67 7.24±2.64 1.092 0.277 Hypertension 9(23.68) 12(15.00) 1.328 0.249 Diabetes 12(31.58) 21(26.25) 0.363 0.547 Long history
of smoking20(52.63) 21(26.25) 7.908 0.005 Pathological type 0.301 0.583 Squamous
carcinoma32(84.21) 64(80.00) Adenocarcinoma 6(15.79) 16(20.00) Clinical staging 0.010 0.920 Ⅰ 12(31.58) 26(32.50) Ⅱ 26(68.42) 54(67.50) Tumour site 1.290 0.256 Upper/Middle
segments34(89.47) 65(81.25) Lower segments 4(10.53) 15(18.75) Surgical time(h) 0.420 0.517 ≤4 18(47.37) 43(53.75) >4 20(52.63) 37(46.25) Intraoperative
haemorrhage(ml)0.209 0.647 ≤500 29(76.32) 64(80.00) >500 9(23.68) 16(20.00) Note: BMI: body mass index. 表 3 感染组和未感染组患者血清β2-MG、sCHE、PSGL-1水平的比较
Table 3 Comparison of serum β2-MG, sCHE, and PSGL-1 levels of patients between infected and uninfected groups
Index Uninfected
group (n=80)Infected
group (n=38)t P β2-MG (μg/L) 3.09±0.86 4.60±0.88 8.846 <0.001 sCHE (kU/L) 4.20±0.89 2.96±0.56 7.871 <0.001 PSGL-1 (U/ml) 254.68±43.25 316.25±44.50 7.159 <0.001 Notes: β2-MG: β2-microglobulin; sCHE: serum cholinesterase; PSGL-1: P-selectin glycoprotein ligand-1. 表 4 不同感染程度患者血清β2-MG、sCHE和PSGL-1水平的比较
Table 4 Comparison of serum β2-MG, sCHE, and PSGL-1 levels by degree of infection
Index Light group
(n=18)Medium group
(n=12)Heavy group
(n=8)F P β2-MG
(μg/L)3.68±0.75 4.96±0.86a 6.15±1.20ab 22.686 <0.001 sCHE
(kU/L)3.54±0.64 2.74±0.53a 2.03±0.41ab 21.118 <0.001 PSGL-1
(U/ml)286.54±40.21 320.74±46.37a 376.38±51.37ab 11.327 <0.001 Notes: a: P<0.05, compared with the light group; b: P<0.05, compared with the medium group. 表 5 食管癌患者术后肺部感染的影响因素分析
Table 5 Influencing factors of postoperative lung infection in patients with esophageal cancer
Factors β SE Wald χ2 P OR 95%CI Long history
of smoking1.275 0.245 27.086 <0.001 3.579 2.214-5.785 β2-MG 1.436 0.356 16.266 <0.001 4.203 2.092-8.445 sCHE −0.667 0.301 4.917 0.027 0.513 0.284-0.925 PSGL-1 1.377 0.468 8.660 0.003 3.964 1.584-9.920 表 6 血清β2-MG、sCHE、PSGL-1评估食管癌患者术后肺部感染的价值
Table 6 Value of serum β2-MG, sCHE, and PSGL-1 in assessing postoperative lung infection in patients with esophageal cancer
Factors AUC 95%CI Sensitivity (%) Specificity (%) Cut-off value β2-MG 0.807 0.724-0.889 76.24 79.57 4.102 μg/L sCHE 0.845 0.774-0.916 78.03 79.12 3.201 kU/L PSGL-1 0.800 0.701-0.900 80.34 77.31 303.142 U/ml Combination 0.954 0.913-0.996 96.26 75.27 - Note: -: no content. -
[1] Watanabe M, Otake R, Kozuki R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer[J]. Surg Today, 2020, 50(1): 12-20. doi: 10.1007/s00595-019-01878-7
[2] Yang L, Jin H, Xie XL, et al. Endoscopic resections for superficial esophageal squamous cell epithelial neoplasia: focus on histological discrepancies between biopsy and resected speimens[J]. BMC Gastroenterol, 2021, 21(1): 114. doi: 10.1186/s12876-021-01694-9
[3] 黄志宁, 柳常青, 郭明发, 等. 充气式纵隔镜联合腹腔镜食管癌切除术的临床分析[J]. 中华外科杂志, 2023, 61(1): 48-53. [Huang ZN, Liu CQ, Guo MF, et al. Clinical analysis of inflatable video-assisted mediastinoscopic transhiatal esophagectomy combined with laparoscopy[J]. Zhonghua Wai Ke Za Zhi, 2023, 61(1): 48-53.] doi: 10.3760/cma.j.cn112139-20220612-00265 Huang ZN, Liu CQ, Guo MF, et al. Clinical analysis of inflatable video-assisted mediastinoscopic transhiatal esophagectomy combined with laparoscopy[J]. Zhonghua Wai Ke Za Zhi, 2023, 61(1): 48-53. doi: 10.3760/cma.j.cn112139-20220612-00265
[4] Li S, Su J, Sui Q, et al. A nomogram for predicting postoperative pulmonary infection in esophageal cancer patients[J]. BMC Pulm Med, 2021, 21(1): 283. doi: 10.1186/s12890-021-01656-7
[5] 叶筱颖, 王子峰, 张娟, 等. 多发性骨髓瘤患者肺部感染病原菌分布特征及血清β2-MG、CRP对肺部感染的诊断价值[J]. 中国病原生物学杂志, 2021, 16(9): 1069-1072. [Ye XY, Wang ZF, Zhang J, et al. Distribution characteristics of pathogens causing a pulmonary infection in patients with multiple myeloma and the diagnostic value of serum β2-MG and CRP in identifying a pulmonary infection[J]. Zhongguo Bing Yuan Sheng Wu Xue Za Zhi, 2021, 16(9): 1069-1072.] Ye XY, Wang ZF, Zhang J, et al. Distribution characteristics of pathogens causing a pulmonary infection in patients with multiple myeloma and the diagnostic value of serum β2-MG and CRP in identifying a pulmonary infection[J]. Zhongguo Bing Yuan Sheng Wu Xue Za Zhi, 2021, 16(9): 1069-1072.
[6] 姚达, 池惠良, 万延辉, 等. 肺癌合并肺部感染患者血清炎性因子水平变化及临床意义[J]. 中华医院感染学杂志, 2019, 29(13): 1959-1962, 1988. [Yao D, Chi HL, Wan YH, et al. Clinical significance of serum inflammatory factors of lung cancer patients complicated with pulmonary infection[J]. Zhonghua Yi Yuan Gan Ran Xue Za Zhi, 2019, 29(13): 1959-1962, 1988.] Yao D, Chi HL, Wan YH, et al. Clinical significance of serum inflammatory factors of lung cancer patients complicated with pulmonary infection[J]. Zhonghua Yi Yuan Gan Ran Xue Za Zhi, 2019, 29(13): 1959-1962, 1988.
[7] 李国干, 程宏宁, 周安燕, 等. COPD并发感染患者PSGL-1、IL-6、膜联蛋白A1的临床价值研究[J]. 分子诊断与治疗杂志, 2021, 13(10): 1652-1655. [Li GG, Cheng HN, Zhou AY, et al. Clinical Value of PSGL-1, IL-6 and Annexin A1 in Patients with COPD Complicated infection[J]. Fen Zi Zhen Duan Yu Zhi Liao Za Zhi, 2021, 13(10): 1652-1655.] doi: 10.3969/j.issn.1674-6929.2021.10.025 Li GG, Cheng HN, Zhou AY, et al. Clinical Value of PSGL-1, IL-6 and Annexin A1 in Patients with COPD Complicated infection[J]. Fen Zi Zhen Duan Yu Zhi Liao Za Zhi, 2021, 13(10): 1652-1655. doi: 10.3969/j.issn.1674-6929.2021.10.025
[8] 国家卫生健康委员会. 食管癌诊疗规范(2018年版)[J]. 中华消化病与影像杂志(电子版), 2019, 9(4): 158-192. [National Health Commission. Oesophageal Cancer Diagnostic and Treatment Guidelines (2018 Edition)[J]. Zhonghua Xiao Hua Bing Yu Ying Xiang Za Zhi (Dian Zi Ban), 2019, 9(4): 158-192.] National Health Commission. Oesophageal Cancer Diagnostic and Treatment Guidelines (2018 Edition)[J]. Zhonghua Xiao Hua Bing Yu Ying Xiang Za Zhi (Dian Zi Ban), 2019, 9(4): 158-192.
[9] 中华人民共和国卫生部. 医院感染诊断标准(试行)[J]. 中华医学杂志, 2001, 81(5): 314-320. [Ministry of Health of the People's Republic of China. Diagnostic criteria for nosocomial infections (proposed)[J]. Zhonghua Yi Xue Za Zhi, 2001, 81(5): 314-320.] doi: 10.3760/j:issn:0376-2491.2001.05.027 Ministry of Health of the People's Republic of China. Diagnostic criteria for nosocomial infections (proposed)[J]. Zhonghua Yi Xue Za Zhi, 2001, 81(5): 314-320. doi: 10.3760/j:issn:0376-2491.2001.05.027
[10] 何荣香, 俞丹, 何英, 等. CPIS评分联合CURB-65评分系统在医院获得性肺炎评价中的作用及价值研究[J]. 中华医院感染学杂志, 2019, 29(2): 300-304. [He RX, Yu D, He Y, et al. Value of CPIS combined with CURB-65 scoring system in evaluation of hospital-acquired pneumonia[J]. Zhonghua Yi Yuan Gan Ran Xue Za Zhi, 2019, 29(2): 300-304.] He RX, Yu D, He Y, et al. Value of CPIS combined with CURB-65 scoring system in evaluation of hospital-acquired pneumonia[J]. Zhonghua Yi Yuan Gan Ran Xue Za Zhi, 2019, 29(2): 300-304.
[11] Xu WW, Zheng CC, Zuo Q, et al. Genome-wide identification of key regulatory lncRNAs in esophageal cancer metastasis[J]. Signal Transduct Target Ther, 2021, 6(1): 88. doi: 10.1038/s41392-021-00476-9
[12] 陈栋, 王培, 马红兵, 等. 食管癌患者外周血CD14+单核细胞TLR4变化与肺部感染的关系[J]. 中华医院感染学杂志, 2022, 32(21): 3287-3291. [Chen D, Wang P, Ma HB, et al. Relationship between change of TLR4 in peripheral blood CD14+mononuclear cells and pulmonary infection in esophageal cancer patients[J]. Zhonghua Yi Yuan Gan Ran Xue Za Zhi, 2022, 32(21): 3287-3291.] Chen D, Wang P, Ma HB, et al. Relationship between change of TLR4 in peripheral blood CD14+mononuclear cells and pulmonary infection in esophageal cancer patients[J]. Zhonghua Yi Yuan Gan Ran Xue Za Zhi, 2022, 32(21): 3287-3291.
[13] 司盼盼, 宁光耀, 卢晨, 等. 食管癌术后并发肺部感染病原菌分布及与患者血清TNF-α IL-1β IL-8的关系[J]. 河北医学, 2022, 28(11): 1854-1860. [Si PP, Ning GY, Lu C, et al. Distribution of Pathogenic Bacteria of Pulmonary Infection after Esophageal Cancer Surgery and Relationship with Serum TNF-α IL-1β and IL-8 of Patients[J]. Hebei Yi Xue, 2022, 28(11): 1854-1860.] doi: 10.3969/j.issn.1006-6233.2022.11.019 Si PP, Ning GY, Lu C, et al. Distribution of Pathogenic Bacteria of Pulmonary Infection after Esophageal Cancer Surgery and Relationship with Serum TNF-α IL-1β and IL-8 of Patients[J]. Hebei Yi Xue, 2022, 28(11): 1854-1860. doi: 10.3969/j.issn.1006-6233.2022.11.019
[14] Qin C, Yang S, Sun X, et al. 18F-FDG PET/CT for Prognostic Stratification of Patients With Extranodal Natural Killer/T-Cell Lymphoma[J]. Clin Nucl Med, 2019, 44(3): 201-208. doi: 10.1097/RLU.0000000000002440
[15] 李宁博, 钟进营, 孙红涛, 等. 保乳手术联合放疗对乳腺癌患者血清肿瘤标志物水平及预后的影响[J]. 癌症进展, 2019, 17(1): 63-65, 100. [Li NB, Zhong JY, Sun HT, et al. Effect of breast-conserving surgery combined with radiotherapy on the levels of serum tumor markers and prognosis in patients with breast cancer[J]. Ai Zheng Jin Zhan, 2019, 17(1): 63-65, 100.] Li NB, Zhong JY, Sun HT, et al. Effect of breast-conserving surgery combined with radiotherapy on the levels of serum tumor markers and prognosis in patients with breast cancer[J]. Ai Zheng Jin Zhan, 2019, 17(1): 63-65, 100.
[16] Huang H, Fan L, Fu D, et al. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center[J]. Ann Palliat Med, 2020, 9(4): 1442-1452. doi: 10.21037/apm-19-589
[17] 陆亚军, 南萍, 龚富婷, 等. 血清β2-MG联合PCT预测多发性骨髓瘤化疗患者肺部感染的价值[J]. 中国国境卫生检疫杂志, 2023, 46(2): 183-187. [Lu YJ, Nan P, Gong FT, et al. Value of serum β2-MG combined with PCT in predicting pulmonary infection in patients with multiple myeloma chemotherapy[J]. Zhongguo Guo Jing Wei Sheng Jian Yi Za Zhi, 2023, 46(2): 183-187.] Lu YJ, Nan P, Gong FT, et al. Value of serum β2-MG combined with PCT in predicting pulmonary infection in patients with multiple myeloma chemotherapy[J]. Zhongguo Guo Jing Wei Sheng Jian Yi Za Zhi, 2023, 46(2): 183-187.
[18] 张淑艳, 申洁, 赵文慧. 老年慢性心力衰竭患者肺部感染后血清胆碱酯酶和胱抑素C及炎症因子分析[J]. 中华医院感染学杂志, 2019, 29(3): 365-368. [Zhang SY, Shen J, Zhao WH. Relationship between serum cholinesterase, cystatin C, inflammation and prognosis in elderly patients with chronic heart failure accompanying pulmonary infection[J]. Zhonghua Yi Yuan Gan Ran Xue Za Zhi, 2019, 29(3): 365-368.] Zhang SY, Shen J, Zhao WH. Relationship between serum cholinesterase, cystatin C, inflammation and prognosis in elderly patients with chronic heart failure accompanying pulmonary infection[J]. Zhonghua Yi Yuan Gan Ran Xue Za Zhi, 2019, 29(3): 365-368.
[19] Brinch JHW, Söderström CM, Gätke MR, et al. Reversal of mivacurium-induced neuromuscular blockade with a cholinesterase inhibitor: A systematic review[J]. Acta Anaesthesiol Scand, 2019, 63(5): 564-575. doi: 10.1111/aas.13304
[20] 侯太辉, 杨涛, 马春敏, 等. 血清SOD和乳酸与胆碱酯酶在重症肺部感染患者中的表达及预测价值[J]. 中华医院感染学杂志, 2020, 30(21): 3263-3267. [Hou TH, Yang T, Ma CM, et al. Expression of serum SOD, lactate and cholinesterase in patients with severe pulmonary infection and predictive value[J]. Zhonghua Yi Yuan Gan Ran Xue Za Zhi, 2020, 30(21): 3263-3267.] Hou TH, Yang T, Ma CM, et al. Expression of serum SOD, lactate and cholinesterase in patients with severe pulmonary infection and predictive value[J]. Zhonghua Yi Yuan Gan Ran Xue Za Zhi, 2020, 30(21): 3263-3267.
[21] 周蕊馨, 陈贝贝, 吴瑜, 等. 血清胆碱酯酶、和肽素水平在机械通气患者并发肺部感染预后评估中的预测效能观察[J]. 实用医院临床杂志, 2023, 20(4): 115-119. [Zhou RX, Chen BB, Wu Y, et al. Observation on the predictive effect of serum cholinesterase and copeptin levels in the prognosis assessment of mechanically ventilated patients complicated with pulmonary infection[J]. Shi Yong Yi Yuan Lin Chuang Za Zhi, 2023, 20(4): 115-119.] doi: 10.3969/j.issn.1672-6170.2023.04.028 Zhou RX, Chen BB, Wu Y, et al. Observation on the predictive effect of serum cholinesterase and copeptin levels in the prognosis assessment of mechanically ventilated patients complicated with pulmonary infection[J]. Shi Yong Yi Yuan Lin Chuang Za Zhi, 2023, 20(4): 115-119. doi: 10.3969/j.issn.1672-6170.2023.04.028
[22] 闫秀文, 赵艺璞, 李亚军, 等. 血清PSGL-1、ANXA1、PCT对COPD急性发作并发肺部感染的诊断价值[J]. 分子诊断与治疗杂志, 2022, 14(2): 274-277, 281. [Yan XW, Zhao YP, Li YJ, et al. Analysis of the diagnostic value of serum PSGL-1, ANXA1 and PCT in acute COPD with pulmonary infection[J]. Fen Zi Zhen Duan Yu Zhi Liao Za Zhi, 2022, 14(2): 274-277, 281.] doi: 10.3969/j.issn.1674-6929.2022.02.024 Yan XW, Zhao YP, Li YJ, et al. Analysis of the diagnostic value of serum PSGL-1, ANXA1 and PCT in acute COPD with pulmonary infection[J]. Fen Zi Zhen Duan Yu Zhi Liao Za Zhi, 2022, 14(2): 274-277, 281. doi: 10.3969/j.issn.1674-6929.2022.02.024
[23] Murakami T, Carmona N, Ono A. Virion-incorporated PSGL-1 and CD43 inhibit both cell-free infection and transinfection of HIV-1 by preventing virus-cell binding[J]. Proc Natl Acad Sci U S A, 2020, 117(14): 8055-8063. doi: 10.1073/pnas.1916055117
[24] Fu Y, He S, Waheed AA, et al. PSGL-1 restricts HIV-1 infectivity by blocking virus particle attachment to target cells[J]. Proc Natl Acad Sci U S A, 2020, 117(17): 9537-9545. doi: 10.1073/pnas.1916054117
[25] 高青, 王宋平, 林福安, 等. 慢性阻塞性肺疾病患者肺部感染病原菌及血清miR-124-3p、PSGL-1、HPT的诊断效能[J]. 中华医院感染学杂志, 2023, 33(15): 2266-2270. [Gao Q, Wang SP, Lin FA, et al. Distribution of pathogenic bacteria in pulmonary infection and diagnostic efficacy of serum miR-124-3p, PSGL-1 and HPT in patients with chronic obstructive pulmonary disease[J]. Zhonghua Yi Yuan Gan Ran Xue Za Zhi, 2023, 33(15): 2266-2270.] Gao Q, Wang SP, Lin FA, et al. Distribution of pathogenic bacteria in pulmonary infection and diagnostic efficacy of serum miR-124-3p, PSGL-1 and HPT in patients with chronic obstructive pulmonary disease[J]. Zhonghua Yi Yuan Gan Ran Xue Za Zhi, 2023, 33(15): 2266-2270.
[26] 赵俊娅, 王珂, 乔博, 等. 心外科ICU患者术后感染血清降钙素原、PSGL-1、sICAM-1与心肌肌钙蛋白Ⅰ的变化及意义[J]. 分子诊断与治疗杂志, 2020, 12(7): 869-873. [Zhao JY, Wang K, Qiao B, et al. Changes and significance of serum procalcitonin, PSGL-1, sICAM-1 and cardiac troponin Ⅰ levels in patients with ICU after cardiac surgery[J]. Fen Zi Zhen Duan Yu Zhi Liao Za Zhi, 2020, 12(7): 869-873.] Zhao JY, Wang K, Qiao B, et al. Changes and significance of serum procalcitonin, PSGL-1, sICAM-1 and cardiac troponin Ⅰ levels in patients with ICU after cardiac surgery[J]. Fen Zi Zhen Duan Yu Zhi Liao Za Zhi, 2020, 12(7): 869-873.